Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification

@article{Kroiss2011FunctionalII,
  title={Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification},
  author={Alexander Stephan Kroiss and D Putzer and Christian Uprimny and Clemens Decristoforo and Michael Gabriel and Wolfram Santner and Christof Kranewitter and Boris Warwitz and Dietmar Waitz and Dorota Kendler and Irene Johanna Virgolini},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2011},
  volume={39},
  pages={543}
}
Purpose 68Ga-DOTA-Tyr3-octreotide positron emission tomography (68Ga-DOTA-TOC PET) has proven to be superior to 111In-DTPA-D-Phe1-octreotide (111In-octreotide) planar scintigraphy and SPECT imaging in neuroendocrine tumours (NETs). Because of these promising results, we compared the accuracy of 123I-metaiodobenzylguanidine (123I-MIBG) imaging with PET in the diagnosis and staging of metastatic phaeochromocytoma and neuroblastoma, referring to radiological imaging as reference standard. 

Citations

Publications citing this paper.

References

Publications referenced by this paper.